Janssen Pharma Says FDA Approves Stelara for Pediatric Patients
July 30 2020 - 5:49PM
Dow Jones News
By Stephen Nakrosis
The Janssen Pharmaceutical Companies of Johnson & Johnson on
Thursday said the U.S. Food and Drug Administration approved its
Stelara to treat pediatric patients with severe plaque
psoriasis.
The company said Stelara, or ustekinumab, "is the first and only
biologic to target interleukin (IL)-12 and IL-23 approved for
pediatric psoriasis use."
The company said the FDA's approval was based on results from
the Cadmus Junior study, a phase 3 clinical trial of 44 patients
that saw 77% achieve clear or almost clear skin at week 12 after
two doses.
Stelara had previously been approved to treat adult
patients.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 30, 2020 17:34 ET (21:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
